BioInnovation Institute welcomes four early-stage start-ups and three university projects to the BII community. Each has been funded with EUR 470K and in the coming 18 months, they will be supported in their business development by the BII team. Amongst the life science innovations are BOOST Pharma from Sweden and Kesmaela Therapeutics from the UK.
While the university projects will continue their work at their current institutions, the four start-ups will have the opportunity to relocate to BII and use BII’s lab- and office facilities. Here, they will work alongside the companies in the Creation House program as well as start-ups in the acceleration program BII Venture Lab which is launching at the beginning of 2021.
Details of the new ventures BII has accepted into the program are as follows:
- BOOST Pharma: A first-in-class treatment for the orphan disease Osteogenesis Imperfecta
- Kesmalea Therapeutics: Accelerating the discovery of novel protein degraders and providing an alternative approach for therapeutics with ‘PROTAC-like’ actions.
- Enduro Genetics: Making biobased production possible at any scale by self-selecting fermentations.
- Research project from Rigshospitalet: A first in class treatment for male infertility.
Three projects at The University of Copenhagen:
- Antagonists for the Lactate Receptor GPR81/ HCAR1 for Treatment of Solid Tumours
- A novel therapeutic approach for treatment of obesity
- A vaccine manufacturing technique for large-scale production of bacterial outer membrane vesicles (OMVs)
If you are interested in joining BII, learn more about the open call for our new program BII Venture Lab